Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Horizon Increases Offer For Depomed
by Ann M. Thayer
July 27, 2015
| A version of this story appeared in
Volume 93, Issue 30
Ireland’s Horizon Pharma has increased its unsolicited, all-stock offer to acquire pain and neurology drugmaker Depomed by 13%. Now at $33.00 per share, a deal would be worth about $2 billion. The offer is contingent on California-based Depomed entering into discussions with Horizon, a specialty and orphan drug firm. Depomed has already rejected previous offers and points out that the most recent one does not increase the amount of Horizon stock that Depomed shareholders would receive or their ownership stake but only reflects a recent rise in Horizon’s stock price.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter